Research ExplorerPublicationsIdelalisib treatment prior to allogeneic stem cell transplan...

Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party

Standard

Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party. / Schetelig, Johannes; Chevallier, Patrice; van Gelder, Michel; Hoek, Jennifer; Hermine, Olivier; Chakraverty, Ronjon; Browne, Paul; Milpied, Noel; Malagola, Michele; Socié, Gerard; Delgado, Julio; Deconinck, Eric; Damaj, Ghandi; Maury, Sebastian; Beelen, Dietrich; Quoc, Stéphanie Nguyen; Shankara, Paneesha; Brecht, Arne; Mayer, Jiri; Hunault-Berger, Mathilde; Bittenbring, Jörg; Thieblemont, Catherine; Lepretre, Stéphane; Baldauf, Henning; de Wreede, Liesbeth C; Tournilhac, Olivier; Yakoub-Agha, Ibrahim; Kröger, Nicolaus; Dreger, Peter.

In: BONE MARROW TRANSPL, Vol. 56, No. 3, 03.2021, p. 605-613.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Schetelig, J, Chevallier, P, van Gelder, M, Hoek, J, Hermine, O, Chakraverty, R, Browne, P, Milpied, N, Malagola, M, Socié, G, Delgado, J, Deconinck, E, Damaj, G, Maury, S, Beelen, D, Quoc, SN, Shankara, P, Brecht, A, Mayer, J, Hunault-Berger, M, Bittenbring, J, Thieblemont, C, Lepretre, S, Baldauf, H, de Wreede, LC, Tournilhac, O, Yakoub-Agha, I, Kröger, N & Dreger, P 2021, 'Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party', BONE MARROW TRANSPL, vol. 56, no. 3, pp. 605-613. https://doi.org/10.1038/s41409-020-01069-w

APA

Schetelig, J., Chevallier, P., van Gelder, M., Hoek, J., Hermine, O., Chakraverty, R., Browne, P., Milpied, N., Malagola, M., Socié, G., Delgado, J., Deconinck, E., Damaj, G., Maury, S., Beelen, D., Quoc, S. N., Shankara, P., Brecht, A., Mayer, J., ... Dreger, P. (2021). Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party. BONE MARROW TRANSPL, 56(3), 605-613. https://doi.org/10.1038/s41409-020-01069-w

Vancouver

Schetelig J, Chevallier P, van Gelder M, Hoek J, Hermine O, Chakraverty R et al. Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party. BONE MARROW TRANSPL. 2021 Mar;56(3):605-613. https://doi.org/10.1038/s41409-020-01069-w

Bibtex

@article{5d417253aa36425f822edd8b3882ed9d,
title = "Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party",
abstract = "No studies have been reported so far on bridging treatment with idelalisib for patients with chronic lymphocytic leukemia (CLL) prior to allogeneic hematopoietic cell transplantation (alloHCT). To study potential carry-over effects of idelalisib and to assess the impact of pathway-inhibitor (PI) failure we performed a retrospective EBMT registry-based study. Patients with CLL who had a history of idelalisib treatment and received a first alloHCT between 2015 and 2017 were eligible. Data on 72 patients (median age 58 years) were analyzed. Forty percent of patients had TP53mut/del CLL and 64% had failed on at least one PI. No primary graft failure occurred. Cumulative incidences of acute GVHD °II-IV and chronic GVHD were 51% and 39%, respectively. Estimates for 2-year overall survival (OS), progression-free survival (PFS), and cumulative incidences of relapse/progression (CIR) and non-relapse mortality NRM were 59%, 44%, 25%, and 31%. In univariate analysis, drug sensitivity was a strong risk factor. For patients who had failed neither PI treatment nor chemoimmunotherapy (CIT) the corresponding 2-year estimates were 73%, 65%, 15%, and 20%, respectively. In conclusion, idelalisib may be considered as an option for bridging therapy prior to alloHCT. Owing to the high risk for acute GVHD intensified clinical monitoring is warranted.",
author = "Johannes Schetelig and Patrice Chevallier and {van Gelder}, Michel and Jennifer Hoek and Olivier Hermine and Ronjon Chakraverty and Paul Browne and Noel Milpied and Michele Malagola and Gerard Soci{\'e} and Julio Delgado and Eric Deconinck and Ghandi Damaj and Sebastian Maury and Dietrich Beelen and Quoc, {St{\'e}phanie Nguyen} and Paneesha Shankara and Arne Brecht and Jiri Mayer and Mathilde Hunault-Berger and J{\"o}rg Bittenbring and Catherine Thieblemont and St{\'e}phane Lepretre and Henning Baldauf and {de Wreede}, {Liesbeth C} and Olivier Tournilhac and Ibrahim Yakoub-Agha and Nicolaus Kr{\"o}ger and Peter Dreger",
year = "2021",
month = mar,
doi = "10.1038/s41409-020-01069-w",
language = "English",
volume = "56",
pages = "605--613",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "3",

}

RIS

TY - JOUR

T1 - Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party

AU - Schetelig, Johannes

AU - Chevallier, Patrice

AU - van Gelder, Michel

AU - Hoek, Jennifer

AU - Hermine, Olivier

AU - Chakraverty, Ronjon

AU - Browne, Paul

AU - Milpied, Noel

AU - Malagola, Michele

AU - Socié, Gerard

AU - Delgado, Julio

AU - Deconinck, Eric

AU - Damaj, Ghandi

AU - Maury, Sebastian

AU - Beelen, Dietrich

AU - Quoc, Stéphanie Nguyen

AU - Shankara, Paneesha

AU - Brecht, Arne

AU - Mayer, Jiri

AU - Hunault-Berger, Mathilde

AU - Bittenbring, Jörg

AU - Thieblemont, Catherine

AU - Lepretre, Stéphane

AU - Baldauf, Henning

AU - de Wreede, Liesbeth C

AU - Tournilhac, Olivier

AU - Yakoub-Agha, Ibrahim

AU - Kröger, Nicolaus

AU - Dreger, Peter

PY - 2021/3

Y1 - 2021/3

N2 - No studies have been reported so far on bridging treatment with idelalisib for patients with chronic lymphocytic leukemia (CLL) prior to allogeneic hematopoietic cell transplantation (alloHCT). To study potential carry-over effects of idelalisib and to assess the impact of pathway-inhibitor (PI) failure we performed a retrospective EBMT registry-based study. Patients with CLL who had a history of idelalisib treatment and received a first alloHCT between 2015 and 2017 were eligible. Data on 72 patients (median age 58 years) were analyzed. Forty percent of patients had TP53mut/del CLL and 64% had failed on at least one PI. No primary graft failure occurred. Cumulative incidences of acute GVHD °II-IV and chronic GVHD were 51% and 39%, respectively. Estimates for 2-year overall survival (OS), progression-free survival (PFS), and cumulative incidences of relapse/progression (CIR) and non-relapse mortality NRM were 59%, 44%, 25%, and 31%. In univariate analysis, drug sensitivity was a strong risk factor. For patients who had failed neither PI treatment nor chemoimmunotherapy (CIT) the corresponding 2-year estimates were 73%, 65%, 15%, and 20%, respectively. In conclusion, idelalisib may be considered as an option for bridging therapy prior to alloHCT. Owing to the high risk for acute GVHD intensified clinical monitoring is warranted.

AB - No studies have been reported so far on bridging treatment with idelalisib for patients with chronic lymphocytic leukemia (CLL) prior to allogeneic hematopoietic cell transplantation (alloHCT). To study potential carry-over effects of idelalisib and to assess the impact of pathway-inhibitor (PI) failure we performed a retrospective EBMT registry-based study. Patients with CLL who had a history of idelalisib treatment and received a first alloHCT between 2015 and 2017 were eligible. Data on 72 patients (median age 58 years) were analyzed. Forty percent of patients had TP53mut/del CLL and 64% had failed on at least one PI. No primary graft failure occurred. Cumulative incidences of acute GVHD °II-IV and chronic GVHD were 51% and 39%, respectively. Estimates for 2-year overall survival (OS), progression-free survival (PFS), and cumulative incidences of relapse/progression (CIR) and non-relapse mortality NRM were 59%, 44%, 25%, and 31%. In univariate analysis, drug sensitivity was a strong risk factor. For patients who had failed neither PI treatment nor chemoimmunotherapy (CIT) the corresponding 2-year estimates were 73%, 65%, 15%, and 20%, respectively. In conclusion, idelalisib may be considered as an option for bridging therapy prior to alloHCT. Owing to the high risk for acute GVHD intensified clinical monitoring is warranted.

U2 - 10.1038/s41409-020-01069-w

DO - 10.1038/s41409-020-01069-w

M3 - SCORING: Journal article

C2 - 33004942

VL - 56

SP - 605

EP - 613

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 3

ER -